Find comprehensive information on Acute Myeloid Leukemia (AML), also known as Acute Myelogenous Leukemia and Acute Myeloblastic Leukemia. This resource offers guidance on AML diagnosis, clinical documentation, and medical coding, including ICD codes and healthcare terminology related to acute myeloid leukemia. Learn about the latest treatment options and research for AML. Improve your understanding of this serious blood cancer for accurate and efficient healthcare documentation.
Also known as
Acute myeloid leukemia
Covers various types of acute myeloid leukemia.
Chronic myeloid leukemia
Includes chronic forms of myeloid leukemia, related to AML.
Other myeloid neoplasms
Encompasses other neoplasms related to myeloid cells, including some AML precursors.
Myelodysplastic syndromes
Includes preleukemic conditions that can evolve into AML.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the AML confirmed by diagnostic testing?
Yes
Is there myelodysplasia-related changes?
No
Do not code AML. Code the presenting signs and symptoms.
When to use each related code
| Description |
|---|
| Acute myeloid leukemia (AML) |
| Chronic myeloid leukemia (CML) |
| Myelodysplastic syndromes (MDS) |
Coding AML requires specific subtype documentation (e.g., M0-M7) for accurate ICD-10-CM code assignment and proper reimbursement.
Misdiagnosis between myelodysplastic syndromes (MDS) and AML can lead to incorrect coding and impact quality reporting and outcomes.
Incomplete documentation of treatment (e.g., chemotherapy, transplant) may affect accurate DRG assignment and hospital reimbursement.
Q: What are the most recent evidence-based diagnostic criteria for differentiating Acute Myeloid Leukemia (AML) from other myeloproliferative neoplasms in adult patients?
A: Differentiating Acute Myeloid Leukemia (AML) from other myeloproliferative neoplasms (MPNs) requires a multi-faceted approach incorporating morphologic, immunophenotypic, cytogenetic, and molecular evaluations. The 2022 World Health Organization (WHO) classification update emphasizes integrating these factors for accurate diagnosis. Specifically, AML diagnosis requires demonstrating at least 20% myeloblasts in the bone marrow or peripheral blood (except in certain subtypes like acute promyelocytic leukemia where specific genetic abnormalities are sufficient). Distinguishing AML from MPNs often hinges on assessing the degree of dysplasia in other lineages, the presence of specific genetic mutations (e.g., FLT3, NPM1, CEBPA for AML; JAK2, CALR, MPL for MPNs), and the clinical presentation. For example, while both AML and some MPNs may present with leukocytosis, AML typically shows a rapid progression with blasts dominating the peripheral blood, whereas MPNs typically exhibit a more indolent course. Explore how comprehensive molecular testing can enhance diagnostic accuracy in differentiating AML from other MPNs. Consider implementing next-generation sequencing (NGS) panels to identify characteristic genetic mutations guiding appropriate treatment strategies.
Q: How do I interpret complex karyotype results in the context of Acute Myeloid Leukemia (AML) prognosis and treatment selection for a newly diagnosed elderly patient?
A: Interpreting complex karyotypes in Acute Myeloid Leukemia (AML), defined as three or more chromosomal abnormalities, carries significant prognostic implications, particularly in elderly patients. Complex karyotypes in AML are generally associated with a poor prognosis, indicating a higher risk of relapse and shorter overall survival. However, the specific abnormalities within the complex karyotype can influence the prognosis further. For example, the presence of monosomal karyotype (loss of an entire chromosome), especially involving chromosomes 5 and/or 7, often confers a particularly adverse prognosis. In elderly patients, who often have a lower tolerance for intensive chemotherapy, the presence of a complex karyotype can influence treatment decisions. Patients with complex karyotypes may benefit from less intensive treatments or clinical trials exploring novel agents, including hypomethylating agents or targeted therapies, rather than standard induction chemotherapy. Learn more about risk stratification strategies for elderly patients with AML based on cytogenetic findings and explore the latest clinical trial data for this patient population.
Patient presents with symptoms suggestive of Acute Myeloid Leukemia (AML), also known as acute myelogenous leukemia or acute myeloblastic leukemia. Presenting complaints include fatigue, unexplained bruising, recurrent infections, and bone pain. Physical examination reveals pallor, petechiae, and possible hepatosplenomegaly. Complete blood count (CBC) demonstrates pancytopenia with circulating blasts. Peripheral blood smear confirms the presence of myeloblasts. Bone marrow biopsy and aspirate are scheduled to confirm the diagnosis and determine the AML subtype according to the WHO classification. Differential diagnosis includes other hematologic malignancies such as acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS). Molecular testing, including cytogenetic analysis and FLT3 mutation testing, will be performed for prognostic stratification and treatment guidance. Initial treatment plan will likely involve induction chemotherapy with cytarabine and an anthracycline, such as daunorubicin or idarubicin. Supportive care measures, including transfusion support and management of infections, will be implemented as needed. Patient education regarding the diagnosis, treatment options, potential side effects, and prognosis will be provided. Referral to a hematologist-oncologist is made for ongoing management of this complex malignancy. ICD-10 code C92.0 will be used for billing purposes. Continued monitoring of complete blood counts, bone marrow response, and adverse events will guide subsequent treatment decisions, which may include consolidation chemotherapy, hematopoietic stem cell transplantation, or targeted therapy.